Design Therapeutics Stock Drops 5.24%: FDA Halts U.S. Trials

Design Therapeutics, Inc. declined 5.24% intraday, with the company announcing the start of the Friedreich ataxia (FA) patient dosing in its RESTORE-FA Phase 1/2 clinical trial. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DT-216P2 in FA patients. However, the FDA has placed a clinical hold on the IND application to open U.S. sites, which may have contributed to the stock's decline.